Transgene SA announced that it has appointed Steven Bloom as Vice President, Chief Business Officer with immediate effect. Steven will join Transgene's executive committee to lead global business development strategy, alliance management and program management of the Company, with a focus on building a strong visibility in the US as part of establishing Transgene as a leader in virus-based immunotherapies worldwide. Mr. Bloom has extensive experience in pharma and biotech licensing, collaborations, M&A, commercial planning and corporate strategy.

He has held senior leadership roles in both large multi-national corporations and biotech companies and has closed major biotech deals in the field of oncology. In particular, he led the Verastem Oncology deal team that acquired duvelisib from Infinity Pharma in November 2016. Prior to joining Transgene, Mr. Bloom was Senior Vice President at Boston Pharmaceuticals and before that he was Chief Business Officer at Vavotar Life Sciences (formerly known as NantiBodyFc).

In his role at Vavotar, Steven Bloom served as a member of the executive leadership team with a specific focus on corporate strategy, business development, and KOL development; he co-led an oncology Antibody Drug Conjugate platform sale and team integration to Sorrento in November 2020. Mr. Bloom held similar roles at Verastem Oncology and Ziopharm Oncology.